INV vs NTLA vs XOMA vs EDIT vs CRSP

For growth investors, XOMA Royalty Corp.

(XOMA) is the stronger pick with 83. 1% revenue growth year-over-year, versus -100. 0% for Editas Medicine, Inc. (EDIT). XOMA Royalty Corp. (XOMA) offers the better valuation at 28. 7x trailing P/E (53. 3x forward), making it the more compelling value choice. Analysts rate Intellia Therapeutics, Inc. (NTLA) a "Buy" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, XOMA Royalty Corp.

(XOMA) delivered a total return of +36. 8%, compared to -90. 1% for Editas Medicine, Inc. (EDIT). Over 10 years, the gap is even starker: CRSP returned +289. 1% versus EDIT's -89. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), XOMA Royalty Corp.

(XOMA) is the lower-risk stock at 1. 16β versus Innventure, Inc. 's 2. 81β — meaning INV is approximately 143% more volatile than XOMA relative to the S&P 500. On balance sheet safety, Innventure, Inc. (INV) carries a lower debt/equity ratio of 4% versus 157% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), XOMA Royalty Corp.

(XOMA) is pulling ahead at 83. 1% versus -100. 0% for Editas Medicine, Inc. (EDIT). On earnings-per-share growth, the picture is similar: XOMA Royalty Corp. grew EPS 188. 5% year-over-year, compared to -143. 1% for Innventure, Inc.. Over a 3-year CAGR, XOMA leads at 105. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XOMA Royalty Corp.

(XOMA) is the more profitable company, earning 60. 8% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XOMA leads at 21. 8% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — XOMA leads at 94. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for EDIT: 60.

8% to $5. 00.

In this comparison, XOMA (0.

7% yield), INV (0. 2% yield) pay a dividend. NTLA, EDIT, CRSP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, XOMA Royalty Corp.

(XOMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 16), 0. 7% yield, +190. 9% 10Y return). Editas Medicine, Inc. (EDIT) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XOMA: +190. 9%, EDIT: -89. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (INV (Financial Services) and NTLA (Healthcare) and XOMA (Healthcare) and EDIT (Healthcare) and CRSP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: INV is a small-cap quality compounder stock; NTLA is a small-cap high-growth stock; XOMA is a small-cap high-growth stock; EDIT is a small-cap quality compounder stock; CRSP is a small-cap quality compounder stock. XOMA pays a dividend while INV, NTLA, EDIT, CRSP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.